Aclaris Therapeutics Inc (NASDAQ: ACRS) on Friday, soared 3.41% from the previous trading day, before settling in for the closing price of $3.81. Within the past 52 weeks, ACRS’s price has moved between $0.80 and $5.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 74.29% over the past five years. The company achieved an average annual earnings per share of 41.73%. With a float of $63.76 million, this company’s outstanding shares have now reached $71.42 million.
Let’s look at the performance matrix of the company that is accounted for 91 employees. In terms of profitability, gross margin is 53.53%, operating margin of -150.31%, and the pretax margin is -138.0%.
Aclaris Therapeutics Inc (ACRS) Insider Updates
Observing investor behavior towards Diagnostics & Research industry stocks is more important than anything else. The insider ownership of Aclaris Therapeutics Inc is 10.73%, while institutional ownership is 75.64%. The most recent insider transaction that took place on Nov 19 ’24, was worth 1,499,998. In this transaction Director of this company bought 666,666 shares at a rate of $2.25, taking the stock ownership to the 710,030 shares. Before that another transaction happened on Aug 05 ’24, when Company’s 10% Owner bought 206,025 for $1.24, making the entire transaction worth $256,357. This insider now owns 14,250,000 shares in total.
Aclaris Therapeutics Inc (ACRS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 41.73% per share during the next fiscal year.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Trading Performance Indicators
Aclaris Therapeutics Inc (ACRS) is currently performing well based on its current performance indicators. A quick ratio of 7.03 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.52, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.52 in one year’s time.
Technical Analysis of Aclaris Therapeutics Inc (ACRS)
Aclaris Therapeutics Inc (NASDAQ: ACRS) saw its 5-day average volume 0.92 million, a negative change from its year-to-date volume of 1.4 million. As of the previous 9 days, the stock’s Stochastic %D was 29.50%. Additionally, its Average True Range was 0.40.
During the past 100 days, Aclaris Therapeutics Inc’s (ACRS) raw stochastic average was set at 69.63%, which indicates a significant increase from 57.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 253.77% in the past 14 days, which was higher than the 118.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.25, while its 200-day Moving Average is $1.47. Nevertheless, the first resistance level for the watch stands at $4.03 in the near term. At $4.12, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.26. If the price goes on to break the first support level at $3.80, it is likely to go to the next support level at $3.67. Assuming the price breaks the second support level, the third support level stands at $3.58.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Key Stats
Market capitalization of the company is 291.04 million based on 71,431K outstanding shares. Right now, sales total 31,250 K and income totals -88,480 K. The company made 4,350 K in profit during its latest quarter, and -7,590 K in sales during its previous quarter.
